Brighton Jones LLC’s Recursion Pharmaceuticals RXRX Stock Holding History

Brighton Jones LLC’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$80.2K	Buy	+26,131	New	+$101K	﹤0.01%	1141
2025 Q4	–	Sell	-27,727	Closed	-$135K	–	766
2025 Q3	$135K	Sell	27,727 -1,582	-5%	-$8.31K	﹤0.01%	983
2025 Q2	$148K	Buy	29,309 +8,156	+39%	+$40.1K	﹤0.01%	879
2025 Q1	$112K	Buy	21,153 +892	+4%	+$6.5K	﹤0.01%	676
2024 Q4	$137K	Buy	20,261 +6,699	+49%	+$45K	﹤0.01%	659
2024 Q3	$89.4K	Buy	+13,562	New	+$97.2K	﹤0.01%	562

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $12.9B AUM 64.92% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

VPM

Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

SoftBank Group Tokyo, Japan $11.4B AUM 27.91% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Brighton Jones LLC's RXRX Position: Q1 2026 in Review

Brighton Jones LLC opened a new position in Recursion Pharmaceuticals (RXRX) in Q1 2026: 26,131 shares worth $80.2K. The stake represents ﹤0.01% of the portfolio and ranks #1141 among its holdings. This is a return to the name: Brighton Jones LLC previously reported a position in RXRX as recently as Q3 2025.

Brighton Jones LLC first reported a position in RXRX in Q3 2024 and has held it in 6 quarters since. The position peaked at $148K in Q2 2025. 335 funds tracked by Wall St. Rank hold RXRX as of Q1 2026.

Brighton Jones LLC held 26,131 shares of Recursion Pharmaceuticals worth $80.2K as of Q1 2026.
Recursion Pharmaceuticals was a new Brighton Jones LLC position in Q1 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Brighton Jones LLC's portfolio in Q1 2026, its #1141 holding.
Brighton Jones LLC first reported a position in Recursion Pharmaceuticals in Q3 2024 and has held it in 6 quarters since.
Brighton Jones LLC's Recursion Pharmaceuticals position peaked at $148K in Q2 2025.
335 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q1 2026.

Based on Brighton Jones LLC's 13F filing for Q1 2026, filed 28 Apr 2026.